As of October 27, 2026, Evogene Ltd. is a publicly traded company (Nasdaq: EVGN). The largest holder reporting an active stake on Schedule 13D is L.I.A. Pure Capital Ltd., at 16.94%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Leon Yehuda Recanati, a director (8.6%) (Schedule 13D/A, October 6, 2026).
About to sign with, pay or invest in Evogene Ltd.? See the free Snapshot first.
Free to see. No signup.
Is Evogene Ltd. a real, registered company?
- Evogene Ltd. files with the SEC under CIK 1574565 (its SEC filings).
- Its shares are listed under the ticker EVGN on Nasdaq (SEC company record).
- Incorporated in L3; business address in Rehovot, L3, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Evogene Ltd. in our court records and SEC 8-K records (as of 2026-10-27).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names L.I.A. Pure Capital Ltd. (filed 2026-10-06).
Who are Evogene Ltd.'s owners and officers?
Evogene Ltd.: business address in Rehovot, L3; industry Agricultural Chemicals (Schedule 13D/A, 2026-10-06).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-02-19)
- : Executive Officer (Form D, 2026-02-19)
- : Executive Officer (Form D, 2026-02-19)
- : Executive Officer (Form D, 2026-02-19)
- : Director (Form D, 2026-02-19)
- : Director (Form D, 2026-02-19)
- : Director (Form D, 2026-02-19)
- : Director (Form D, 2026-02-19)
- : Director (Form D, 2026-02-19)
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-10-06 | L.I.A. Pure Capital LTD. | 16.94% |
| Schedule 13D/A, 2026-09-11 | L.I.A. Pure Capital LTD. | 19.35% |
| Schedule 13D/A, 2026-09-11 | Recanati Leon | 8.6% |
| Schedule 13D/A, 2026-08-28 | L.I.A. Pure Capital LTD. | 19.35% |
| Schedule 13G/A, 2026-08-14 | Armistice Capital, LLC | 4.99% |
| Schedule 13D/A, 2026-08-13 | Recanati Leon | 8.6% |
| Schedule 13D/A, 2026-08-13 | L.I.A. Pure Capital LTD. | 19.35% |
| Schedule 13D, 2026-08-11 | Recanati Leon | 5.7% |
| Schedule 13D/A, 2026-08-07 | L.I.A. Pure Capital LTD. | 15.98% |
| Schedule 13D/A, 2026-07-27 | L.I.A. Pure Capital LTD. | 17.41% |
| Schedule 13D/A, 2026-07-20 | L.I.A. Pure Capital LTD. | 16.81% |
| Schedule 13D, 2026-07-10 | L.I.A. Pure Capital LTD. | 12.61% |
Want the whole picture on Evogene Ltd.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Evogene Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Evogene Ltd. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Evogene Ltd. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 1,343,886 shares (15.4% of shares outstanding) (Form 4, 2026-09-30).
- , the chief financial officer: 4,100 shares (0.05% of shares outstanding) (Form 3, 2026-03-18).
- , the chief development officer: 1,129 shares (0.01% of shares outstanding) (Form 4, 2026-08-26).
Shares outstanding: 8,718,193 as of 2025-12-31, from the company's latest SEC cover page.
How much has Evogene Ltd. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-02-19 | $3.38M | $3.38M |
| Form D, 2024-09-04 | $0 | $12.02M |
Latest IPO step: Evogene Ltd. filed to go public (F-1, 2024-09-19).
IPO filings: F-1, 2024-09-19; ticker EVGN on Nasdaq Capital Market.
Keep reading
More on Evogene Ltd. and the records around it.
Evogene Ltd. elsewhere on the record
- 5%+ stake filings Oct 2026
- Form D filing Feb 2026
Companies that share a holder
- RECANATI LEON also filed stake reports on 1 other company: KAMADA LTD (Mar 2026)
- L.I.A. Pure Capital Ltd. also filed stake reports on 10 other companies: Quantum X Labs Inc. (formerly known as Viewbix Inc.) (Aug 2026), Rail Vision Ltd. (Aug 2026), Clearmind Medicine Inc. (May 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Arcadia Biosciences, Inc. (Aug 2026), Aridis Pharmaceuticals, Inc. (Aug 2026), Autolus Therapeutics plc (Aug 2026)
Related pages
Funding and filing history5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/evogene-ltd